Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Neoplasms, Unknown Primary × ivosidenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Leukemia, Myeloid, Acute 2 Leukemia 2 Cholangiocarcinoma 2 Neoplasms, Unknown Primary 1 Glioma 1

Interventions

Paclitaxel 6 Carboplatin 6 Gemcitabine 3 Irinotecan 2 Erlotinib Hydrochloride 2 Capecitabine 2 Bevacizumab 2 sintilimab 1 pertuzumab 1 pemigatinib 1 olaparib 1 ivosidenib 1 ipatasertib 1 etoposide phosphate 1 erythromycin propionate-N-acetylcysteinate 1 entrectinib 1 cobimetinib 1 belinostat 1 atezolizumab 1 antineoplaston AS 2-1 1 antineoplaston A10 1 alectinib 1 Vemurafenib 1 Oxaliplatin 1 HhAntag691 1 Everolimus 1 Etoposide 1 Cisplatin 1 CP protocol 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03498521 2025-11-19

CUPISCO

Hoffmann-La Roche

Phase 2 Completed

529 enrolled 16 charts

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡